CO172 Indirect Treatment Comparison of Efficacy and Safety of Capivasertib-Fulvestrant Versus Alpelisib-Fulvestrant for PIK3CA-Altered, HR-Positive, Advanced Breast Cancer after Disease Progression Following Endocrine-Based Therapy
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.258
https://www.valueinhealthjournal.com/article/S1098-3015(24)00373-5/fulltext
Title :
CO172 Indirect Treatment Comparison of Efficacy and Safety of Capivasertib-Fulvestrant Versus Alpelisib-Fulvestrant for PIK3CA-Altered, HR-Positive, Advanced Breast Cancer after Disease Progression Following Endocrine-Based Therapy
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00373-5&doi=10.1016/j.jval.2024.03.258
First page :
Section Title :
Open access? :
No
Section Order :
11609